Miller-Meeks Leads Bipartisan Push to Cap Insulin Prices at $35

September 3, 2026 Press Release WASHINGTON, D.C. — Congresswoman Mariannette Miller-Meeks, M.D. (IA-01) is leading efforts on the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026, bipartisan legislation that caps out-of-pocket insulin costs at $35 a month for Americans on private insurance, building on the fight Miller-Meeks has led since 2022 to make insulin affordable. "As a physician, I have watched patients ration a medicine that keeps them alive because they couldn't afford the bill," said Congresswoman Miller-Meeks . "In 2022, I was one of only 12 Republicans to cross party lines and vote to pass the Affordable Insulin Now Act, capping insulin at $35 a month for Medicare seniors. That fight isn't finished until every American with diabetes, not just seniors, has that same protection. This bill finishes the job." “Insulin insecurity is not a partisan issue. It’s a life-or-death issue,” said Rep. DeGette (CO-01) . “I have fought for years to lower the price of insulin for the over 40 million Americans living with diabetes. I have met with too many Coloradans who have shared their painful experience of rationing their insulin so they could afford groceries. No one in America should be forced to choose between their life-saving medication or feeding their families.” “As a doctor with Type 1 diabetes who depends on insulin, I understand the immediate need to bring down the cost of insulin – especially at a time when so many Americans are already struggling with high costs,” said Congresswoman Schrier. “I am proud to introduce this groundbreaking bipartisan legislation that will cap the price of insulin for all Americans and make a meaningful difference in the lives and the health of everyone in our districts.” “Diabetes stole the lives of 100,000 Americans last year. Tens of millions of Americans are living with diabetes, and for many, insulin is a matter of life and death,” said Rep. Bresnahan. “No American should have to choose between paying the bills and getting the insulin they need, or risk their life rationing the doses they have left. This legislation isn’t just a Band-Aid on the problem. It delivers immediate relief for patients and reforms that will increase competition and drive down prices over the long term. Lowering the cost of insulin puts money back where it belongs: in the pockets of working families who need every dollar they earn. Middlemen and big corporations shouldn’t be making extra cash off the backs of working people who rely on insulin to survive.” What the INSULIN Act of 2026 Does: Caps what you pay for insulin at $35 a month, with no deductible, if you have private health insurance, the same protection Medicare seniors already have. Makes sure insurance companies can't dodge the cap with paperwork, no more requiring special approval or extra hoops just to get your insulin at the capped price. Requires plans to cover the type of insulin you actually need, not just one product that may not work for you. Helps uninsured Americans find free or low-cost insulin through a new 24/7 hotline and resource center. Speeds up FDA approval for more affordable insulin competitors when there aren't enough on the market, helping bring prices down over time, not just capping them. Background: In March 2022, Miller-Meeks was one of only 12 House Republicans to cross party lines and vote to pass the Affordable Insulin Now Act , capping insulin costs at $35 a month for Americans on Medicare. That bill passed the House but did not become law on its own. The $35 Medicare insulin cap was later enacted as part of the Inflation Reduction Act, a nearly $740 billion package that Miller-Meeks opposed over its broader spending and tax provisions. The INSULIN Act of 2026 builds on the policy Miller-Meeks has supported since 2022, extending the same $35 cap to the millions of Americans covered by private insurance who were left out of the original protection. What Patient and Medical Groups Are Saying: The American Diabetes Association (ADA): “The American Diabetes Association (ADA) appreciates and applauds the House’s bipartisan introduction of the INSULIN Act, which would limit out-of-pocket insulin costs for patients at $35 a month. A recent survey, commissioned by ADA, showed that 40% of insulin users currently pay $150 each month, and there is widespread bipartisan support across the U.S. for making insulin affordable. The INSULIN Act would ensure no one has to choose between paying for insulin and other necessities. This bill puts people first and is a commonsense way to lower health care costs for Americans depending on insulin to live.” Breakthrough T1D : “For the more than 1.5 million Americans with type one diabetes (T1D), insulin access is life-or-death,” said Breakthrough T1D Chief Global Advocacy Officer Lynn Starr . “By capping out-of-pocket cost at $35, the INSULIN Act ensures that people have dependable, affordable access to the insulin they require to live. We applaud Representatives DeGette, Miller-Meeks, Schrier, and Bresnahan for introducing the House INSULIN Act and urge their colleagues to stand with them on the side of all those living with T1D. While there is still more work to be done, we are hopeful that, together with the Senate, we will finally have the access to affordable insulin the entire T1D community deserves and depends on.” Endocrine Society: “For the millions of Americans who rely on insulin every day, no one should have to choose between paying for their medication and meeting other basic needs. The Endocrine Society applauds Representatives DeGette, Schrier, Miller-Meeks, and Bresnahan for introducing the INSULIN Act, which would help make insulin more affordable for people with private insurance while connecting uninsured patients to resources that can help them access this life saving medication. This bipartisan legislation is an important step toward ensuring that all people who need insulin can obtain it and stay healthy.” - Robert Lash, MD, Chief Medical Officer To read the full bill text, click HERE . ### Issues : Delivering Results Health